EMA Begins Setting Up New Bodies To Tackle Medical Product Shortages
April Workshop To Be Held To Explain Agency's Expanded Role
A new EU regulation has come into effect that gives the European Medicines Agency wider powers to monitor, prevent and manage shortages of drugs and medical devices in public health emergencies. A number of steering groups and other bodies and networks are being set up to put the new systems into action.
You may also be interested in...
The EU NIS 2 Directive Is Here. What Does It Mean For Medtech?
The EU Network and Information Security (NIS) Directive 2 entered into force this year, replacing the original NIS Directive. Cybersecurity is at the heart of NIS 2, and some of the new provisions are particularly important for the medtech and health sector.
MDR And IVDR – Similar Step Ups, Varying Commercial Impacts
Medtech Insight spoke to the CEOs of two companies that recently had very different experiences with the new European IVDR and MDR regulations to gauge their thoughts on any potential commercial impacts.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.